Source: Oasmia Pharmaceutical AB
Data showing the efficacy and benefits of the recently approved cancer drug Paclical, as compared to current paclitaxel treatment, poised for continued growth in Russia and CIS countries.
Oasmia Pharmaceutical AB (OASM),
or the "Company," a developer of a new generation of drugs within human
and veterinary oncology, recently presented clinical data at the 19th
annual Russian Cancer Congress that illustrate the efficacy and
benefits of the Company's recently approved cancer drug Paclical.
The data, which were presented by Russian lead oncologists Professor
Tjulandin and Dr. Chekini, were well received by the many oncologists in
attendance at the event, positioning the drug for further growth in the
Russian market.
The Company's
presentation elaborated on the results from the extensive clinical
program indicating that Paclical possesses efficacy which is equal to
current standard treatment, albeit with several benefits such as
allowing for higher doses, shorter infusion times and no premedication.
In addition, a recently published study showed that Paclical is
bioequivalent with Abraxane(r), the current market leader
within the segment. Abraxane's net sales are expected to be in the range
of $1 billion to $1.25 billion in 2015, according to research analyst Zacks.
"We are pleased that Paclical has generated this significant volume of
interest among oncologists attending such a high profile conference and
the Company's presentation," said Julian Aleksov, Executive Chairman of
Oasmia. "It shows that our product has tremendous potential to gain
substantial market share in Russia and the CIS, which the magnitude of
our initial orders from Russia also indicate. We are very confident that
future development coupled with the sales efforts by our distribution
partner in the region will be very beneficial for Oasmia, ultimately
increasing the Company's revenue and achieving value on behalf of our
shareholders."
The 19th
annual Russian Cancer Congress took place from November 17-19 in Moscow
and is the largest oncologist conference held annually in Russia.
About Paclical
Paclical is a water-soluble formulation of paclitaxel and Oasmia's
patented excipient, XR-17. Paclitaxel is one of the most widely used
anti-cancer substances and is included in the standard treatment of a
variety of cancers such as lung cancer, breast cancer and ovarian
cancer. Paclical consists of a freeze dried powder dissolved in
conventional solution for infusion. In April 2015, Paclical received a
marketing authorization for treatment of ovarian cancer in the Russian
Federation.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field
of human and veterinary oncology. The company's product development
aims to create and manufacture novel nanoparticle formulations and
drug-delivery systems based on well-established cytostatics which, in
comparison with current alternatives, show improved properties, reduced
side-effects, and expanded applications. The company's product
development is based on its proprietary in-house research and company
patents. Oasmia is listed on NASDAQ Stockholm (OASM.ST), Frankfurt Stock
Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ USA (OASM.US).
No comments:
Post a Comment